ArticleNature protocols2018
Microfabrication of AngioChip, a biodegradable polymer scaffold with microfluidic vasculature.
Article in Nature protocols, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Engineering adaptive self-healing biomaterials from jammed microfluidic elastomeric particles.Materials today. Bio · 2026Article
- Heart-on-a-chip and vasculature-on-a-chip platforms as models of cardiovascular disease.Nature reviews. Cardiology · 2026Review
- Vascularized Cardiac Tissue Engineering: From Advances in Biofabrication to Translational Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The role of agrin as a downstream mediator of Slit3 in osteogenic-angiogenic interaction under osteoporosis.Regenerative biomaterials · 2026Article
- Microfluidic technologies for wearable and implantable biomedical devices.Lab on a chip · 2025Review
- Strategies for the vascular patterning of engineered tissues for organ repair.Nature biomedical engineering · 2025Review
- Cell driven elastomeric particle packing in composite bioinks for engineering and implantation of stable 3D printed structures.Bioactive materials · 2025Article
- Bioengineering vascularization.Development (Cambridge, England) · 2024Review
- Hydrogel-Based Vascularized Organ Tissue Engineering: A Systematized Review on Abdominal Organs.Gels (Basel, Switzerland) · 2024Review
- Endothelial extracellular vesicles enhance vascular self-assembly in engineered human cardiac tissues.Biofabrication · 2024Article
- Structure-function integrated biodegradable Mg/polymer composites: Design, manufacturing, properties, and biomedical applications.Bioactive materials · 2024Review
- Advances in cardiac tissue engineering and heart-on-a-chip.Journal of biomedical materials research. Part A · 2024Review
- High-Resolution Additive Manufacturing of a Biodegradable Elastomer with A Low-Cost LCD 3D Printer.Advanced healthcare materials · 2024Article
- Biofabrication methods for reconstructing extracellular matrix mimetics.Bioactive materials · 2024Review
- Engineering Organ-on-a-Chip Systems for Vascular Diseases.Arteriosclerosis, thrombosis, and vascular biology · 2023Review
- Facile Photopatterning of Perfusable Microchannels in Synthetic Hydrogels to Recreate Microphysiological Environments.Advanced materials (Deerfield Beach, Fla.) · 2023Article
- Elastomeric Polyesters in Cardiovascular Tissue Engineering and Organs-on-a-Chip.Biomacromolecules · 2023Review
- Development of Organs-on-Chips and Their Impact on Precision Medicine and Advanced System Simulation.Pharmaceutics · 2023Review
- Vascularized organ bioprinting: From strategy to paradigm.Cell proliferation · 2023Review
- Organ-on-a-chip technologies for biomedical research and drug development: A focus on the vasculature.Smart medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microengineered biomimetic systems for organ-on-a-chip or tissue engineering purposes often fail as a result of an inability to recapitulate the in vivo environment, specifically the presence of a well-defined vascular system. To address this limitation, we developed an alternative method to cultivate three-dimensional (3D) tissues by incorporating a microfabricated scaffold, termed AngioChip, with a built-in perfusable vascular network. Here, we provide a detailed protocol for fabricating the AngioChip scaffold, populating it with endothelial cells and parenchymal tissues, and applying it in organ-on-a-chip drug testing in vitro and surgical vascular anastomosis in vivo. The fabrication of the AngioChip scaffold is achieved by a 3D stamping technique, in which an intricate microchannel network can be embedded within a 3D scaffold. To develop a vascularized tissue, endothelial cells are cultured in the lumen of the AngioChip network, and parenchymal cells are encapsulated in hydrogels that are amenable to remodeling around the vascular network to form functional tissues. Together, these steps yield a functional, vascularized network in vitro over a 14-d period. Finally, we demonstrate the functionality of AngioChip-vascularized hepatic and cardiac tissues, and describe direct surgical anastomosis of the AngioChip vascular network on the hind limb of a Lewis rat model.
Indexed as
Identifiers
30072724What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.